Probable predictive biomarkers for tumor reaction to mTOR inhibitors, as are described in glioblastoma, breast and prostate cancer cells, would be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Therefore, this details relies on preclinical assays, according to in vitro c